| Sep 12 |
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
|
| Sep 12 |
GSK, CureVac mRNA flu shot reaches late-stage studies
|
| Sep 12 |
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
|
| Sep 9 |
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
|
| Aug 21 |
News Flash: 8 Analysts Think CureVac N.V. (NASDAQ:CVAC) Earnings Are Under Threat
|
| Aug 18 |
CureVac Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 15 |
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
|
| Aug 15 |
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
|
| Aug 15 |
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
|
| Aug 14 |
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
|
